In BRAF-mutated melanoma, a phase II study of dabrafenib and trametinib for patients with brain metastases demonstrated intracranial response rates of 44–59% in cohorts stratified by BRAF mutation type, prior CNS therapy, symptoms, and performance status. The gene discussed is BRAF; the disease is melanoma.